Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-08-09 00:00:00 ET · period of report 2022-08-05 · accession 0001209191-22-045023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-09 | 2022-08-05 | SPRY | Shawver Laura | CEO, Dir | M - OptEx | $1.27 | +78.7K | 254.2K | +45% | +$100.0K |
| D | 2022-08-09 | 2022-08-05 | SPRY | Shawver Laura | CEO, Dir | M - OptEx | $0.00 | -78.7K | 403.0K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-05 | M | A | 78,740 | $1.27 | 254,242 | D | — | — | |
| 2 | Derivative | Stock option (right to buy) | 2022-08-05 | M | D | 78,740 | $0.00 | 402,997 | D | $1.27 · — to 2030-04-28 | 78,740 Common Stock | (F1) 25% of the shares vested on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter. |